This Plexus Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday

Shares of semiconductor companies are trading higher after the Anthropic-Akamai deal demonstrated industry demand. Also, Meta's Muse AI agent strengthens the case for continued spending on CPUs, GPUs and AI infrastructure.

Shares of semiconductor companies are trading higher amid overall market strength and easing inflation concerns as investors return to AI-related companies.

Critical Metals, Priority Technology, Meta Platforms And Other Big Stocks Moving Higher On Monday

U.S. stocks rose Monday, with Nasdaq up 1%. Critical Metals jumped 38% on Greenland deal news as tech and other shares broadly gained.

Bull of the Day: AXT (AXTI)

AXT, a semiconductor substrate manufacturer, is positioned as a critical supplier for AI data-center optical interconnects, particularly in indium phosphide (InP) substrates. The company reported record Q2 2026 revenue of $47.6M (up 165% YoY) with 44.9% gross margins and a 170% EPS beat. With a >$100M backlog, planned capacity expansions to $35M quarterly by end-2026 and $65-70M by 2027/early 2028, and progression toward 6-inch wafers, AXT is transitioning from a cyclical substrate maker into a critical AI infrastructure supplier. However, risks include potential slowdown in AI optical spending, China export controls, and margin sustainability.

8-K filing — Faeth Therapeutics, Inc. (FTH)

Filed: 2026-09-17 AccNo: 0001193125-26-394360 Size: 150 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Guggenheim Initiates Coverage On Faeth Therapeutics with Buy Rating, Announces Price Target of $70

Guggenheim analyst Brad Canino initiates coverage on Faeth Therapeutics (NASDAQ:FTH) with a Buy rating and announces Price Target of $70.